medRxiv preprint doi: https://doi.org/10.1101/2020.05.05.20092015; this version posted May 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Title: Smoking Prevalence is Low in Symptomatic Patients Admitted for COVID-19.

Authors: Nicola Gaibazzi, Domenico Tuttolomondo, Angela Guidorossi, Andrea Botti, Andrea Tedeschi, Chiara Martini, Maria Mattioli

Corresponding Author: Maria Mattioli, MD, Department of Non-invasive Cardiology, Parma University Hospital, Via Gramsci 14, Parma, 43126, Italy

Telephone number +39 0521 704629

Fax number +39 0521 702189

E-mail address maria.mattioli@hotmail.it

Authors' affiliations:

Department of Non-invasive Cardiology, Cardiology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy (Nicola Gaibazzi, Domenico Tuttolomondo, Angela Guidorossi, Andrea Botti, Andrea Tedeschi, Maria Mattioli)

Radiology Department, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy (Chiara Martini)

List of abbreviations:

ACE-2	angiotensin-converting enzyme 2
COVID-19	coronavirus disease 2019
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2

Short title: Smoking in Patients admitted for COVID-19

Keywords: COVID-19 – cigarette smoking – angiotensin-converting enzyme 2

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.05.20092015; this version posted May 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

There is currently little information regarding the role of active smoking in predisposing to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Basic science suggests that higher angiotensin-converting enzyme (ACE-2) expression in the tissues of smokers may predispose to infection, but in fact the role of ACE-2 in coronavirus disease 2019 (COVID-19) is far from being understood (1).

The few published studies reporting smoking rates in patients with COVID-19 actually point right to the opposite direction; in fact, the prevalence of smokers among COVID-19 patients in China has been reported between 1.4% and 12.6% (2-4), and also recent data coming from the New York City outbreak confirm the low prevalence of smokers in COVID-19 patients, in this case at 5.1% (5).

These prevalence figures are so much lower than the corresponding national smoking rates (age class matched) in the overall population (32.4% in 45-64 y/o or 25.1% in >65 y/o in China or 16.3% in 45-64 y/o or 8.4%>65 y/o in US (see http://www.tcrc.org.cn/UploadFiles/2016-03/318/201603231215175500.pdf,https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm) that they urge to test whether these findings are confirmed also in a third Country heavily involved in the COVID-19 outbreak, as it is the case for Northern Italy. This would strengthen the hypothesis of a true inverse association between smoke habit and predisposition to SARS-CoV-2 infection.

The current retrospective case series includes 441 patients with confirmed COVID-19, who were consecutively admitted between March 5 and March 31, 2020, at a tertiary referral center in Parma, Northern Italy, an Italian hospital heavily involved in the recent outbreak. Cases were confirmed through reverse-transcriptase–polymerase-chain-reaction assays, performed on nasopharyngeal swab specimens. Demographic information, laboratory, clinical variables and in-hospital mortality were collected during hospital stay and manually extracted from electronic health records; supplementary efforts were made to directly contact patients (or their relatives) to confirm the

medRxiv preprint doi: https://doi.org/10.1101/2020.05.05.20092015; this version posted May 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

smoking status reported in the charts (423 out of 441 patients/relatives were actually successfully reached by phone).

This observational study was approved by the institutional review board of Parma University Hospital (371/2020/OSS/AOUPR). Written informed consent was waived due to the emergency state caused by the outbreak.

441 patients (**Table 1**) formed the final study group of consecutive laboratory-confirmed COVID-19 patients; 273 (62%) patients were males. Median age was 71 y/o, 156 patients (35%) died during hospitalization and 285 (65%) were discharged because clinically healed. 21 patients (5%) were active smokers and 44 (10%) were ex-smokers, while 376 (85%) were non-smokers.

Male sex, history of prior cardiovascular disease, D-dimer and C-reactive protein were significantly more prevalent (or higher) in the subgroup of 156 patients who died during hospital stay, compared with 285 patients discharged alive. There was on the contrary no significant difference regarding the prevalence of smokers in the two subgroups.

Italy is one of the European Country with the highest number of deaths from COVID-19. Based on the sources of data used in this study, 441 COVID-19 patients were admitted between 5 and 31 March 2020. Active smokers were only 21 and this number corresponds to less than 5% prevalence of active smokers, which is disproportionately low compared with the 14.9% prevalence of smokers in the 65-74 age class (matching the median age of 71 y/o in our study) in the general Italian population ($p<0.001$) (http://dati.istat.it/Index.aspx?QueryId=15513).

The very low prevalence of smokers in our COVID-19 cohort seemingly replicates the findings that can be derived from descriptive tables in Chinese reports and also in the US report from New York City (2-5).

Since the study is limited by lack of inclusion of asymptomatic patients, the suggestion of a low prevalence of active smokers in COVID-19 should be confined to symptomatic and hospitalized patients. Another limitation is that individual drug therapy data during hospital stay is not available, although this is not supposed to influence the smoking history prevalence, which was collected at admission.

The current study suggests that smokers might carry some type of protective mechanism from symptomatic SARS-CoV-2 infection, although this should be confirmed in specifically-designed, controlled studies (2-5).

medRxiv preprint doi: https://doi.org/10.1101/2020.05.05.20092015; this version posted May 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Only speculations can be done regarding the mechanism leading to this lower prevalence of smokers among COVID-19 patients admitted to hospital. Exposure to smoke has been shown to modulate immune and adaptive immune responses and reduce systemic levels of several immune/inflammation markers, when compared with never smokers. Thus, smoking could attenuate the normal defensive function of the immune system, which becomes tolerant of a continuous inflammatory insult, while the immune system of non-smokers may be more prone to the SARS-CoV-2 hyperacute cytokine release syndrome. Moreover, ACE-2 overexpression could interfere with virus-mediated downregulation of ACE-2, a mechanism already known to boost lung damage mediated by renin-angiotensin-aldosterone system in severe acute respiratory syndrome coronavirus 1 infection (6).

Whatever the mechanism, if this hypothetical protective effect in active smokers is finally confirmed, it could help unravel the underlying molecular mechanism predisposing to SARS-CoV-2 infection, then being also potentially exploitable by appropriately targeted protective drugs.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.05.20092015; this version posted May 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. Demographics, Clinical and Laboratory Characteristics of Patients with COVID-19 admitted in Parma, Northern Italy, between March 5 and March 31, 2020

	No. (%)			
Characteristic	Total	Alive	Dead	*P* value
No. of patients	441	285 (64.6)	156 (35.4)	-
Male	273 (61.9)	161 (58.6)	112 (71.8)	0.002
Age, median [interquartile range], y	71 [18]	67 [20]	76 [10]	$P = 0.76$[a]
Current Smoker	21 (4.8)	11 (3.9)	10 (6.4)	0.333
Prior Smoker	44 (10)	30 (10.5)	14 (9)	0.723
Non smoker	376 (85.3)	244 (85.6)	132 (84.6)	0.887
Comorbidities				
Hypertension	254 (57.6)	159 (55.8)	95 (60.9)	0.349
Diabetes	92 (20.9)	51 (17.9)	41 (26.3)	0.051
Prior cardiovascular disease	63 (14.3)	30 (10.5)	33 (21.2)	0.004
Laboratory				
D-dimer, median [interquartile range], ng/mL	863 [8749]	736 [730]	1172 [1597]	$P < 0.001$ [a]
C-Reactive Protein [interquartile range], mg/L	130 [158]	107 [138]	163 [148]	$P < 0.001$ [a]

[a] variables expressed as median (interquartile range) compared with Mann-Whitney U test.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.05.20092015; this version posted May 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Total word count: 778

Funding/Support: None.

Conflict of Interest Disclosures: None reported.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.05.20092015; this version posted May 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

1. Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J Med* 2020;382(17):1653-9.

2. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020.

3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395(10223):497-506.

4. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020;382(18):1708-20.

5. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. *N Engl J Med* 2020.

6. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 2005;11(8):875-9.